EVERSANA unveils new AI-powered pharmacovigilance suite
EVERSANA has launched a new pharmacovigilance (PV) platform that answers the need to apply advanced data analytics and artificial intelligence to drug safety monitoring and risk management.
The new EVERSANA ORCHESTRATE PV solution has grown out of an alliance forged between EVERSANA and AI specialist Quantiphi, along with tech giant Oracle. It aims to streamline pharmacovigilance workflows, including literature monitoring and aggregate authoring and reporting, to help manufacturers monitor drug safety more effectively in an increasingly complex pharmaceutical market.
Pharmacovigilance – which monitors the lifecycle of pharmaceutical products, from clinical trials to post-marketing surveillance – has undergone dramatic changes in the last few years as it has transformed from a largely manual process, with a lack of integration with real-world data sources, to one that can use digital technologies to tap into new methods for data collection, management, and analysis.
That has allowed the discipline to shift from a reactive activity, which can be plagued by inconsistent reporting, to one based on proactive monitoring that draws on digital technologies like AI, natural language processing (NLP), and automation.
For instance, AI algorithms can scan electronic health records (EHRs), social media, and scientific literature to detect signals of adverse drug events, while NLP allows systems to interpret unstructured data, such as patient narratives and online forums, which were previously underutilised sources of safety information.
According to EVERSANA, its new platform can speed up PV processes by as much as 50% while reducing the manual labour needed by up to 40%.
"Today we bring pharmacovigilance leaders the long-overdue intelligent, scalable solution to complex and costly PV workflows," said Jim Lang, chief executive of EVERSANA, which is pharmaphorum's parent company. He added that the product launch ties in with the company's mission to 'pharmatise' AI, applying it to help companies overcome challenges in commercialising new drugs and therapies.
"Through the power of our ORCHESTRATE operating system, our best-in-class experts in drug safety, and rapidly evolving AI solutions, we're streamlining safety processes, ensuring global compliance, and helping influence better patient outcomes," he added.
The new PV platform comes just a few months after it launched EVERSANA ORCHESTRATE MLR, an AI-powered toolkit designed to make medical, legal, and regulatory (MLR) review processes more accurate and efficient.
